SYNTEX NAPROSYN/ANAPROX SALES JUMP 19% TO $205.2 MIL. IN FOURTH QUARTER

Executive Summary

Combined worldwide sales of Syntex' Naprosyn (naproxen) and Anaprox (naproxen sodium) jumped 19.4% to $205.2 mil. in the fourth quarter (ended July 31). Sales from the two NSAIDs were up 8% for the fiscal year at $802.5 mil. In the last three months, U.S. sales of Naprosyn and Anaprox jumped 22.1% to $148.4 mil. Naprosyn's share of new prescriptions hit 18.2% in the quarter, a turnaround from a low of 16% in March 1989. Non-U.S. fourth quarter sales rose 12.9%. to $56.8 mil. New products generated approximately $40 mil. in sales and accounted for 45% of the increase in human pharmaceutical sales in the fourth quarter, Syntex said. For the year, revenues from Toradol, Synarel, Cytovene and Cardene totaled approximately $105 mil. Syntex worldwide human pharmaceutical sales climbed 26.6% to $336.5 mil. for the quarter and 13.1% at $1.271 bil. for the year. Corporate revenues rose 13% for the year to $1.5 bil. Net income jumped 49% in the quarter to $75.1 mil., and was 12.6% higher for the year at $341.5 mil.